Abstract
Surgical treatment of pancreatic cancer often leads to the development of diabetes mellitus (DM) due to the loss of a significant mass of functioning pancreatic tissue. Currently, the possibility of using stem cells (SC) to restore the islet apparatus of the pancreas and treat diabetes resulting from surgery for pancreatic cancer is being studied. The review examines various sources of SC, methods of their isolation and differentiation into insulin-producing cells. Special attention is paid to the advantages and disadvantages of SC allo- and xenotransplantation, as well as the prospects for stimulating endogenous proliferation of pancreatic beta cells. The potential of SC therapy in improving glycemic control and reducing the need for insulin therapy in patients with diabetes after pancreatic resection is emphasized, however, further research is needed to optimize SC therapy methods and evaluate its long-term efficacy and safety in this group of patients.
Keywords: stem cells, pancreatic cancer, pancreatogenic diabetes, xenotransplantation, allotransplantation.
For citation: Kaliberdenko V.B., Vorontsova E.O., Alustaeva E.V., Samatov E.R., Bondarenko M.T., Aramyan E.E., Zinchenko M.S. Stem cells in the treatment of diabetes caused by surgical treatment of pancreatic cancer. Clinical review for general practice. 2025; 6 (6): 53–56 (In Russ.). DOI: 10.47407/kr2025.6.6.00630
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
